Skip to main content
Search
Search
    Quick Search anywhere
    Quick search in Citations
Advanced Search
Skip main navigationClose Drawer MenuOpen Drawer Menu
Previous article
Next article
Original communication

Prevalent use of high-intensity statin therapy and LDL-C target attainment among PAD patients undergoing angioplasty

A single-center retrospective cross-sectional analysis

Published Online:September 02, 2022https://doi.org/10.1024/0301-1526/a001025

Abstract

Summary:Background: The global burden of peripheral arterial disease (PAD) is substantial. Reducing the major modifiable risk factors for noncommunicable disease, including dyslipidaemia, represents a public health priority. Aim is to evaluate the prevalent adequate use of lipid-lowering therapy (LLT) and low-density lipoprotein cholesterol (LDL-C) attainment among patients with PAD of the lower extremities undergoing percutaneous transluminal angioplasty. Patients and methods: We screened PAD patients treated at the University Hospital Zurich (January 2012–December 2018). We excluded patients <18 years, without classifiable severity of PAD, or with missing LDL-C or medication data. In this cross-sectional study, we studied the prevalent LLT use and LDL-C values in target according to the most recent European guidelines. Available clinical data included demographic information, lipid profile, type and dose of LLT, characteristics of the artery obstruction and angioplasty. Results: A total of 2,148 angioplasties were performed in 956 patients: 614 (64%) were men; the mean age was 70.6 (SD 11.4) years. A total of 608 (64%) had a non-critical PAD (Fontaine stage I–IIb), whereas the remaining had a critical limb ischemia or a diabetic foot syndrome. Their median LDL-C value was 2.00 (Q1–Q3: 1.50–2.60) mmol/L. In accordance to the 2016 and 2019 European Society of Cardiology guidelines, the LDL-C target of 1.8 and 1.4 mmol/L was not reached in 63% (n=599) and in 79% (n=760) of patients, respectively. Only 41% (n=390) of patients were on high-intensity statin therapy. Conclusions: The attainment of LDL-C targets, as recommended by current European guidelines, and the use of high-intensity LLT were unsatisfactory in the majority of PAD patients.

References

  • 1 Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7:e1020–30. First citation in articleCrossref Medline, Google Scholar

  • 2 Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140–205. First citation in articleCrossref Medline, Google Scholar

  • 3 Spence JD, Dresser GK. Overcoming challenges with statin therapy. J Am Heart Assoc. 2016;5:e003497 First citation in articleCrossref Medline, Google Scholar

  • 4 Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81. First citation in articleCrossref Medline, Google Scholar

  • 5 Sagris M, Katsaros I, Giannopoulos S, Rosenberg RD, Altin SE, Rallidis L, et al. Statins and statin intensity in peripheral artery disease. A systematic review and meta-analysis. Vasa. 2022;51:198–211. First citation in articleGoogle Scholar

  • 6 Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: A systematic review and meta-analysis. JAMA. 2018;319:1566–79. First citation in articleCrossref Medline, Google Scholar

  • 7 Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058. First citation in articleCrossref Medline, Google Scholar

  • 8 Ference BA, Cannon CP, Landmesser U, Lüscher TF, Catapano AL, Ray KK. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur Heart J. 2018;39:2540–5. First citation in articleCrossref Medline, Google Scholar

  • 9 Hsu CCT, Kwan GNC, Singh D, Rophael JA, Anthony C, van Driel ML. Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia. Cochrane Database of Syst Rev. 2018;12:CD009195. First citation in articleMedline, Google Scholar

  • 10 Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol. 2022;29:5–115. First citation in articleCrossref Medline, Google Scholar

  • 11 Shishehbor MH, Jaff MR. Percutaneous therapies for peripheral artery disease. Circulation. 2016;134:2008–27. First citation in articleCrossref Medline, Google Scholar

  • 12 Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2019;2020(41):255–323. First citation in articleGoogle Scholar

  • 13 Güneş Y, Sincer I, Erdal E. Catheter-directed intra-arterial thrombolysis for lower extremity arterial occlusions. Anatol J Cardiol. 2019;22:54–9. First citation in articleMedline, Google Scholar

  • 14 Townsend N, Kazakiewicz D, Wright FL, Timmis A, Huculeci R, Torbica A, et al. Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol. 2022;19:133–43. First citation in articleCrossref Medline, Google Scholar

  • 15 Arya S, Khakharia A, Binney ZO, DeMartino RR, Brewster LP, Goodney PP, et al. Association of statin dose with amputation and survival in patients with peripheral artery disease. Circulation. 2018;137:1435–46. First citation in articleCrossref Medline, Google Scholar

  • 16 Dopheide JF, Veit J, Ramadani H, Adam L, Papac L, Vonbank A, et al. Adherence to statin therapy favours survival of patients with symptomatic peripheral artery disease. Eur Heart J Cardiovasc Pharmacother. 2021;7:263–70. First citation in articleCrossref Medline, Google Scholar

  • 17 Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107. First citation in articleCrossref Medline, Google Scholar

  • 18 Dopheide JF, Papac L, Schindewolf M, Baumgartner I, Drexel H. Poor attainment of lipid targets in patients with symptomatic peripheral artery disease. J Clin Lipidol. 2018;12:711–7. First citation in articleCrossref Medline, Google Scholar

  • 19 Presta V, Figliuzzi I, Miceli F, Coluccia R, Fogacci F, Cicero AFG, et al. Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. Atherosclerosis. 2019;285:40–8. First citation in articleCrossref Medline, Google Scholar

  • 20 Fox KM, Tai MH, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107:380–8. First citation in articleCrossref Medline, Google Scholar

  • 21 Sagris M, Katsaros I, Giannopoulos S, Rosenberg DR, Altin SE, Rallidis L, Mena-Hurtado C, Armstrong JE, Kokkinidis DG. Statins and statin intensity inperipheral artery disease: A systematic review and meta-analysis. Vasa. 2022;51:198–211. First citation in articleLink, Google Scholar

  • 22 Hoeks SE, Scholte op Reimer WJ, van Gestel YR, Schouten O, Lenzen MJ, Flu WJ, et al. Medication underuse during long-term follow-up in patients with peripheral arterial disease. Circ Cardiovasc Qual Outcomes. 2009;2:338–43. First citation in articleCrossref Medline, Google Scholar

  • 23 Gebauer K, Wintersohl K, Kraska R, Kortendick K, Fahrland U, Freisinger E, et al. Medication-based secondary prevention in patients with peripheral arterial occlusive disease: An analysis based on secondary data. Herz. 2021;46 Suppl 2:280–6. First citation in articleCrossref Medline, Google Scholar

  • 24 Chen DC, Armstrong EJ, Singh GD, Amsterdam EA, Laird JR. Adherence to guideline-recommended therapies among patients with diverse manifestations of vascular disease. Vasc Health Risk Manag. 2015;11:185–92. First citation in articleCrossref Medline, Google Scholar

  • 25 Kamil S, Sehested TSG, Houlind K, Lassen JF, Gislason GH, Dominguez H. Trends in use of cardioprotective medication in peripheral artery disease: a nationwide study. J Am Heart Assoc. 2021;10:e020333. First citation in articleCrossref Medline, Google Scholar

  • 26 Cholesterol Treatment Trialists C. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393:407–15. First citation in articleCrossref Medline, Google Scholar

  • 27 Reston JT, Buelt A, Donahue MP, Neubauer B, Vagichev E, McShea K. Interventions to improve statin tolerance and adherence in patients at risk for cardiovascular disease: a systematic review for the 2020 US Department of Veterans Affairs and US Department of Defense guidelines for management of dyslipidemia. Ann Intern Med. 2020;173:806–12. First citation in articleCrossref Medline, Google Scholar